435 related articles for article (PubMed ID: 34068917)
1. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of NAD
Ghanem MS; Caffa I; Monacelli F; Nencioni A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
[TBL] [Abstract][Full Text] [Related]
3. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Hasmann M; Schemainda I
Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
5. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
6. NAMPT: A critical driver and therapeutic target for cancer.
Gasparrini M; Audrito V
Int J Biochem Cell Biol; 2022 Apr; 145():106189. PubMed ID: 35219878
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
[TBL] [Abstract][Full Text] [Related]
8. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
[TBL] [Abstract][Full Text] [Related]
9. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Lucas S; Soave C; Nabil G; Ahmed ZSO; Chen G; El-Banna HA; Dou QP; Wang J
Recent Pat Anticancer Drug Discov; 2017; 12(3):190-207. PubMed ID: 28637419
[TBL] [Abstract][Full Text] [Related]
12. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
[TBL] [Abstract][Full Text] [Related]
13. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
14. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
[TBL] [Abstract][Full Text] [Related]
15. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase regulates cell survival through autophagy in cardiomyocytes.
Hsu CP; Hariharan N; Alcendor RR; Oka S; Sadoshima J
Autophagy; 2009 Nov; 5(8):1229-31. PubMed ID: 19855187
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.
Galli U; Colombo G; Travelli C; Tron GC; Genazzani AA; Grolla AA
Front Pharmacol; 2020; 11():656. PubMed ID: 32477131
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
